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Abstract 
Background: Opioid-induced hyperalgesia (OIH) is well-documented in preclinical studies but findings 
of clinical studies are less consistent.  The objective was to undertake a systematic review and meta-
analysis of studies examining evidence for OIH in humans following opioid exposure. 
Methods: Systematic electronic searches utilised six research databases (Embase, Medline, PubMed, 
Cinahl Plus, Web of Science and OpenGrey).  Manual ‘grey’ literature searches were also undertaken.  
The PICOS framework was used to develop search strategies and findings are reported in accordance 
the PRISMA Statement.  Data synthesis and subgroup analyses were undertaken using a random 
effects model (DerSimonian-Laird method). 
Results: A total of 6167 articles were identified.  Following abstract and full text reviews, 26 articles 
(involving 2706 participants) were included in the review.  There was evidence of OIH, assessed by 
pain tolerance, in response to noxious thermal (hot and cold) stimuli but not electrical stimuli.  There 
was no evidence of OIH when assessing pain detection thresholds.  OIH was more evident in patients 
with opioid use disorder, than in patients with pain, and in patient groups treated with NMDA 
receptor antagonists (primarily evidenced in methadone-maintained populations). 
Conclusions: OIH was evident in patients following chronic opioid exposure but findings were 
dependent upon pain modality and assessment measures.  Further studies should consider 
evaluating both pain threshold and pain tolerance across a range of modalities to ensure assessment 
validity.  Significant subgroup findings suggest that potential confounders of pain judgements – such 
as illicit substance use, affective characteristics or coping styles – should be rigorously controlled in 
future studies. 
 
Keywords: Hyperalgesia; Pain Threshold; Pain; Analgesics, Opioid; Opioid-related disorders. 
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Introduction 
Rationale 
Prolonged use of opioids is associated with a number of debilitating side effects, including 
the potential for the development of tolerance, dependence and abuse.  The development 
of opioid-induced hyperalgesia (OIH) may represent substantial additional challenges in the 
effective treatment of pain.  Whilst OIH has been well-documented in preclinical studies, 
evidence in clinical populations is relatively sparse and inconsistent; therefore, elucidation of 
this phenomenon is of key importance to anaesthetists and other pain specialists.  Whilst 
the apparent clinical effects of increasing opioid tolerance, opioid withdrawal and OIH may 
be the same (i.e. increased experience of pain), the physiological aetiologies likely differ and, 
therefore, effective management may require different approaches.  Development of 
effective policy and practice necessitates synthesis of existing clinical evidence and to 
provide recommendations for future work in this area of study. 
 
Several studies have documented hyperalgesia in response to systemic or intrathecal 
morphine at high doses and reported that pain is further potentiated following dose 
increases
1 2 3 4
.  Furthermore, hyperalgesia has been shown to be positively associated with 
baseline morphine-equivalent dose, even after adjusting for pain diagnosis, pain duration, 
pain severity and opioid withdrawal symptoms
5
.  Furthermore, this study demonstrated that 
opioid tapering was associated with decreased hyperalgesia; however, it should be noted 
that the mean morphine-equivalent dose was relatively low.  In a more recent study
6
, 
hyperalgesia was reported to be significantly associated with high-dose intra-operative 
remifentanil treatment compared with remifentanil with naloxone (an opioid antagonist) 
and low-dose remifentanil. 
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Whilst there are several proposed central and peripheral mechanisms, such as alpha-2 
adrenoceptors and the endocannabinoid system, the most prominent of these is considered 
to be the potential role of the central glutaminergic system
7
, suggesting that opioid 
exposure increases N-methyl-D-aspartate (NMDA) activity.  Indeed, several studies have 
reported down-regulation of spinal glutamate receptors following prolonged opioid 
exposure, resulting in spinal neuron sensitisation
8 9 10 11
.  This further substantiates the 
hypothesised role of NMDA receptors in hyperalgesic states. 
 
The method of pain assessment is an important consideration when examining OIH.  The 
two prominent methods are patient rating scales and quantitative sensory testing (QST).  
There are a number of potential limitations associated with the use of rating scales.  First, in 
order to distinguish between tolerance and hyperalgesia, it may be considered wise to test 
experimental pain models at non-painful sites – rather than to obtain an overall rating of 
pain – which is difficult to achieve using rating scales but can be achieved using QST.  
Secondly, in the presence of persistent and debilitating pain, a ‘ceiling effect’ may arise 
when participants initially report their pain severity as the worst possible pain imaginable 
(i.e. a rating of ‘10/10’).  QST enables testing at non-painful sites, thereby ensuring a 
baseline pain score of zero.  Indeed, all studies included in the present review conducted 
pain assessments using QST at non-painful sites.  This method has been used in the 
assessment of most experimental pain modalities, including thermal and electrical pain, and 
has been shown to be effective in predicting responses to treatment
12
. 
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Objectives 
The core objective of this study was to undertake a systematic review and meta-analysis of 
studies examining evidence for OIH in humans following opioid exposure.  The secondary 
objectives were to examine subgroups and to attempt to explain any heterogeneity found in 
study effects.  Three subgroup variables were used to examine three further hypotheses 
based on the above suggested mechanisms: evidence of OIH will differ by treatment group 
(pain or opioid use disorder); OIH will be negatively associated with opioids with NMDA 
receptor antagonist properties; and OIH will be positively associated with increasing opioid 
treatment dose. 
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Methods 
The established PICOS framework (Population, Interventions, Comparators, Outcomes and 
Study design) was used to design the current review and to develop an appropriate search 
strategy.  The findings are reported in accordance with the recommendations set out in the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
13
.  The 
structure of the current paper is based on the PRISMA 27-item checklist.  The PRISMA four-
phase flow diagram was used to show eligibility screening procedures (Figure 1). 
 
Protocol and registration 
The review protocol was registered on PROSPERO, the international database of 
prospectively registered systematic reviews in health and other related domains of study.  
The protocol registration number is CRD42017058513 and it can be accessed at 
https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017058513. 
 
Eligibility criteria 
Populations were included if they were human and in receipt of opioid therapy for the 
treatment of either opioid use disorder or pain.  Animal models and in vitro models were 
excluded. 
Interventions took the form of opioid therapy.  Data were extracted from all studies where 
participants were exposed to opioids for 1 month or more.  Studies were excluded if they 
focused on acute opioid exposure (<1 month) – i.e. primarily the delivery of opioids during 
the perioperative period and exposure in healthy volunteers. 
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Comparator populations were included from several clinical settings and study designs.  
Healthy volunteers were included as were patients in receipt of non-opioid analgesics when 
compared with opioid exposure in patients with pain.  Single-sample repeated measures 
designs were also included if patients initiated opioid treatment. 
Outcomes were extracted for three experimental pain modalities: thermal (cold and heat); 
electrical; and mechanical pressure.  They were confined to findings from quantitative 
sensory testing (QST) techniques.  Studies were excluded if they relied upon patient-
reported pain, such as visual analogue scales (VAS) or numerical rating scales (NRS) assessing 
pain intensity.  Regarding mechanical stimuli, articles provided different metrics (e.g. kPa, 
Newtons, oz, etc.).  An attempt was made to convert means and standard deviations to one 
consistent metric (kPa); however, the converted values differed, implausibly, by two orders 
of magnitude and were not deemed to be reliable.  In consequence, data for mechanical 
stimuli were not pooled.  This discrepancy may have resulted from insufficient data reported 
in original articles – e.g. a measure of force, but not area, was reported in these articles; for 
example, ‘Newtons’ rather than ‘Newtons per m
2
’ or ‘Newtons per cm
2
’.  The appropriate 
authors were contacted for clarification; however, no responses were received.  
Computations were attempted using the appropriate SI unit (Newtons per m
2
 in this 
particular example); however, in the absence of definitive information, this may not have 
accurately reflected the force applied in studies.  Data from the remaining modalities were 
pooled. 
Study designs that were excluded were secondary data (to avoid duplication of articles 
presenting primary data) and case reports (due to the absence of control data). 
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Information sources 
Electronic searches were undertaken using: Embase; Medline; PubMed; Cinahl Plus; Web of 
Science and OpenGrey.  Searches were run on 1 April 2017, and no language or date 
restrictions were applied.  In an attempt to avoid publication bias, a broad manual grey 
literature search was undertaken; this included examination of conference proceedings, 
technical reports, organisation websites and dissertations.  At a later stage, once included 
articles had been identified, a manual reference search was undertaken of these included 
articles. 
 
Search 
The search term was constructed using the PICOS principles, shown below, and was run in 
each of the electronic databases.  The participants filter (human only) was applied where 
available (Embase, Medline and PubMed). 
Population: opi* 
Intervention: Not included in search strategy 
Comparators: Not included in search strategy 
Outcomes: hyperalg* OR OIH OR “pain sensit*” OR “pain toler*” OR PTO OR “pain thresh*” 
OR PTR 
Study design: Not included in search strategy 
 
Study selection 
Initially, articles underwent title and abstract review.  Where articles clearly did not meet 
inclusion criteria, they were excluded, and the reason for exclusion was recorded.  
Remaining articles underwent full text eligibility review, in light of careful consideration of 
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the inclusion and exclusion criteria, and the reason for each article excluded at this stage 
was recorded.  A random selection of 25% of included articles was assessed by a second 
reviewer who was blind to title, author, journal and year of publication. 
 
Data collection process 
A data extraction proforma was designed and piloted with 5 of the included articles.  Whilst 
it was evident that there would not be a full complement of data available for subgroup 
analyses, all items were retained in the proforma for assessment following the extraction of 
available data from all included articles.  Where required, authors were contacted in an 
effort to seek clarification of the data presented in articles.  A number of issues were 
encountered and, in the interests of transparency, they are discussed in this section.  First, 
several studies reported findings visually and, therefore, the data extracted from these 
articles were obtained from graphs rather than precise numerical reports.  Secondly, where 
studies reported data at individual patient lev l, means and standard deviations were 
calculated.  Thirdly, where data were reported at subgroup level only (e.g. ‘buprenorphine 
group’ and ‘methadone group’), the overall means and standard deviation were calculated 
to facilitate the Cochrane-recommended single pairwise comparison
14
.  An exception was 
made for the paper by Hay and colleagues
15
, in order to facilitate two pairwise comparisons 
(pain versus controls and opioid use disorder versus controls).  In this case, the Cochrane 
recommendation to half the control group
14
 was used. 
 
Data items 
The data items that were extracted for each study (where available) were: author(s); article 
title; date of publication; study design; number recruited and final number included in 
sample; treatment group (opioid use disorder or pain); demographic characteristics (gender 
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composition, mean age and ethnic composition); psychiatric characteristics (depression and 
anxiety scores); duration of pain (where applicable); prescription drug information (name of 
drug, length of exposure to drug and mean morphine-equivalent daily dose); core outcomes 
(pain threshold and tolerance values); pain modality; evidence of attempts to control for 
tolerance; evidence of use of opioids with NMDA receptor antagonist properties (e.g. 
pethidine, levorphanol, methadone, dextropropoxyphene, and ketobemidone); and 
additional notes (free text box in which explanatory notes or issues for consideration were 
recorded).  It should be noted, however, that adjusted effect values were not reported for 
many of these variables, including demographic characteristics and psychiatric morbidity.  In 
consequence, several of the planned subgroup analyses were not undertaken. 
 
Risk of bias in individual studies 
Assessment of risk of bias in individual studies was undertaken at study level.  Study design 
was identified using Agency for Healthcare Research and Quality AHRQ (US DoH) criteria
16
.  
Risk of bias assessment was achieved using instruments designed by the National Institutes 
of Health (NIH)
17 18
.  These instruments are not intended to be summed to provide a total 
score, since assigning scores may be considered to be misleading
19
.  Instead, these 
instruments are designed to prompt consideration of the key concepts relating to internal 
validity and potential risk of bias in individual study designs.  As such, study quality was rated 
as: ‘poor’; ‘fair’; or ‘good’. 
 
Summary measures 
The principal measure used in the primary meta-analysis and in subgroup analyses was 
standardised mean difference (SMD) between exposed and control groups.  This was 
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entered into the software as mean group pain threshold and pain tolerance values, standard 
deviations around the mean and number of participants in each group. 
 
Synthesis of results 
Pooled study effect estimates were generated using the random effects model 
(DerSimonian-Laird method).  Individual studies were weighted in accordance with the 
principle of inverse variance and, since a random effects model was applied, this included 
between-study variance in addition to within-study variance.  The preferred I
2
 statistic
20
 was 
used to classify heterogeneity.  Definitive heterogeneity thresholds can be misleading; 
however, as per guidance in the Cochrane Handbook
14
 (section 9.5.2), we accepted that 
≥50% may represent substantial heterogeneity. 
 
Risk of bias across studies 
Publication bias was assessed using the Egger regression intercept bias detection test rather 
than the Begg-Mazumdar rank correlation test since, comparatively, it is more sensitive to a 
range of bias types and does not lose power to the same degree when assessing a smaller 
number of studies.  The use of imputational strategies in meta-analyses remains 
controversial and, furthermore, is unlikely to alter the conclusions in over 90% of secondary 
data analyses
21
.  In consequence, imputational strategies were not used in the current 
review. 
 
Additional analyses 
Subgroup analyses were undertaken in an effort to examine secondary hypotheses and 
meta-regression (DerSimonian-Laird method) was performed in an attempt to explain 
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substantial heterogeneity.  Subgroup analyses were undertaken based on treatment 
characteristics: treatment for opioid use disorder or pain; whether or not the opioid had 
NMDA receptor antagonist properties; and opioid dose used in treatment.  Morphine-
equivalent doses were established using an online equianalgesic calculator based on the American 
Pain Society guidelines and critical review papers focusing on the issue of equianalgesic dosing 
(http://clincalc.com/opioids/).  Buprenorphine was not available for conversion in the equianalgesic 
calculator so the Monthly Index of Medical Specialities (MIMS) conversion ratio (x80) was applied.  
Further subgroup analyses were planned for a range of demographic and clinical 
characteristics but, due to insufficient data, were not undertaken.  Within the scope of the 
current review there were insufficient studies to undertake meta-regression with more than 
one subgroup variable in each analysis. 
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Results 
Study selection 
Electronic searches identified 6121 articles and a further 46 were identified through manual 
searches.  A total of 1831 duplicates were identified resulting in a total of 4336 articles 
retained for eligibility review.  Figure 1 shows the number of articles excluded during both 
abstract and full text review and reasons for exclusion.  Data were extracted from 26 articles, 
involving a total of 2706 participants.  An independent review was undertaken with a 
random 25% sample of included articles and there were no discrepancies between 
reviewers. 
 
[Insert Figure 1 around here] 
 
Several articles addressed more than one assessment metric and/or pain modality.  The 
number of samples drawn from these 26 articles, by research question, is shown in Figure 2. 
 
[Insert Figure 2 around here] 
 
Study characteristics 
The characteristics of included studies are shown in Table 1, and further information 
concerning the group breakdown and group characteristics can be found in the 
supplementary material (Table 2).  Where the outcome measures for the current review 
were not a primary objective or were not the only primary objective, the study design was 
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reported for the method used to obtain the relevant data rather than the method used in 
the overall study. 
 
[Insert Table 1 around here] 
 
Risk of bias within studies 
All studies were identified as being of either ‘good’ or ‘fair’ quality; none were excluded due 
to being of ‘poor’ quality. 
 
Synthesis of results 
Pain threshold 
Pain threshold (PTR) in response to noxious thermal (cold) stimuli (k=13), measured in 
seconds of exposure to pain detection, was slightly lower in exposed patients compared with 
controls (SMD = -0.61; 95% CI = -1.553 to 0.331) but the difference was not statistically 
significant.  PTR in response to noxious thermal (cold) stimuli (k=5), measured in degrees 
Celsius to pain detection, was slightly higher in exposed patients compared with controls 
(SMD = 0.79; 95% CI = -0.444 to 2.026) but the difference was not statistically significant.  
One study reported PTR in response to noxious thermal (heat) stimuli, measured in seconds 
of exposure to pain detection
31
.  Findings were very similar for exposed patients and 
controls whereby the noxious heat stimulus was tolerated for 42 seconds and 41 seconds, 
respectively.  PTR in response to noxious thermal (heat) stimuli (k=5), measured in degrees 
Celsius to pain detection, was slightly lower in exposed patients compared with controls 
(SMD = -1.43; 95% CI = -2.936 to 0.075) but the difference was not statistically significant. 
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PTR in response to noxious electrical stimuli (k=6), measured in volts to pain detection, was 
significantly higher in exposed patients compared with controls (SMD = 1.28; 95% CI = 0.471 
to 2.090; p<0.001).  Substantial heterogeneity was identified in study effects (I
2
=81.87).  Five 
of the six study samples that underwent PTR assessment in response to noxious electrical 
stimuli also underwent PTR assessment in response to noxious thermal (cold) stimuli 
measured in seconds of exposure to pain detection.  Contrary to the findings of electrical 
experimental pain, the findings relating to thermal (cold) pain, in the same samples, lay in 
the opposite direction.  The weighted standardised mean difference between exposed 
patients and controls was shown to be -0.772 (95% CI = -1.414 to -0.130), indicating 
significantly lower PTR in exposed patients compared with controls (p=0.018). 
 
Pain tolerance 
Pain tolerance (PTO) was evaluated in response to noxious thermal (cold and heat) and 
noxious electrical stimuli.  Findings are reported in Figure 3. 
 
[Insert Figure 3 around here] 
 
Figure 3 shows that PTO in response to noxious thermal (cold) stimuli (k=19), measured in 
seconds tolerated, was significantly lower in exposed patients compared with controls (SMD 
= -1.83; 95% CI = -2.458 to -1.208; p<0.001).  Substantial heterogeneity was identified in 
study effects (I
2
=96.09). 
 
Two studies reported PTO in response to noxious thermal (cold) stimuli, measured in 
degrees Celsius tolerated
21 44
, and, in both studies, exposed patients were associated with 
lower tolerance levels than were controls.  Exposed patients tolerated temperatures of 3.30 
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and 3.88 degrees Celsius, respectively, as compared with 0.50 and 0.56 degrees Celsius, 
respectively, in the control groups. 
 
One study reported PTO in response to noxious thermal (heat) stimuli, measured in seconds 
tolerated
31
.  Findings were identical for exposed patients and controls whereby the noxious 
heat stimulus was tolerated for 45 seconds in both groups. 
 
[Insert Figure 4 around here] 
 
Figure 4 shows that PTO in response to noxious thermal (heat) stimuli (k=3), measured in 
degrees Celsius tolerated, was significantly lower in exposed patients compared with 
controls (SMD = -4.17; 95% CI = -8.258 to -0.079; p=0.046).  Substantial heterogeneity was 
identified in study effects (I
2
=99.19). 
 
PTO in response to noxious electrical stimuli (k=7), measured in volts tolerated, was slightly 
lower in exposed patients compared with controls (SMD = -0.30; 95% CI = -0.996 to 0.405) 
but the difference was not statistically significant.  Six of the seven study samples that 
underwent PTO assessment in response to noxious electrical stimuli also underwent PTO 
assessment in response to noxious thermal (cold) stimuli, measured in seconds tolerated.  
Contrary to the PTO findings in response to noxious electrical stimuli, the findings relating to 
thermal (cold) stimuli in the same samples were associated with significant group 
differences.  The weighted standardised mean difference between exposed patients and 
controls was shown to be -4.571 (95% CI = --6.568 to –2.574), indicating significantly lower 
PTO in exposed patients compared with controls (p<0.001). 
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Risk of bias across studies 
Assessment of risk of publication bias was undertaken for articles in significant pain 
modalities and showed fairly symmetrical distributions suggesting no significant publication 
bias.  This was confirmed by the Egger regression intercept: pain threshold in response to 
electrical stimuli (t=2.44; df=4; p=0.071); pain tolerance in response to cold stimuli measured 
in seconds (t=1.95; df=17; p=0.068); and pain tolerance in response to heat stimuli measured 
in degrees Celsius (t=0.97; df=1; p=0.510). 
 
Additional analyses 
Subgroup analyses were undertaken in an effort to further examine significant differences 
between exposed patients and controls.  Subgroup analyses were performed, using meta-
regression, for pain modalities and assessment measures associated with significant 
standardised mean differences between exposed patients and controls in the overall 
findings (PTR in response to noxious electrical stimuli; PTO in response to noxious thermal 
(cold) stimuli measured in seconds tolerated; and PTO in response to noxious thermal (heat) 
stimuli measured in degrees Celsius tolerated).  Subgroup analyses were run separately for 
three variables (treatment group, NMDA receptor antagonism and opioid dose).  Substantial 
heterogeneity had been anticipated, hence the a priori decision to employ the use of a 
random effects model.  Additionally, where significant subgroup differences were identified, 
appropriate variables were entered into meta-regression models in an effort to explain the 
overall variance in study effects. 
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Subgroup analyses and examination of heterogeneity of study effects: Pain threshold (PTR) 
in response to noxious electrical stimuli, measured in volts tolerated 
Pooled effect estimates of PTR in response to noxious electrical stimuli differed significantly 
by treatment group (p<0.001).  There was a significantly greater difference between exposed 
patients and controls in studies assessing patients with opioid use disorder (SMD = 1.54; 95% 
CI = 0.575 to 2.499; k = 5) compared with studies assessing patients with pain (SMD = 0.22; 
95% CI = -0.537 to 0.985; k = 1), indicating elevated pain sensitivity in patients with opioid 
use disorder compared to patients with pain.  Meta-regression generated a non-significant 
model. 
 
Pooled effect estimates of PTR in response to noxious electrical stimuli differed significantly 
by NMDA receptor antagonist treatment (p=0.006).  There was a significantly greater 
difference between exposed patients and controls in studies where NMDA receptor 
antagonists were used (SMD = 1.29; 95% CI = 0.175 to 2.398; k = 5) compared with opioids 
with no NMDA receptor antagonist properties (SMD = 0.71; 95% CI = -0.096 to 1.507; k = 3), 
indicating elevated pain sensitivity in patients treated with NMDA receptor antagonists.  
Meta-regression generated a non-significant model. 
 
Pooled effect estimates of PTR in response to noxious electrical stimuli did not differ 
significantly as a function of prescribed opioid dose and, in consequence, did not account for 
variance in overall study effects. 
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Subgroup analyses and examination of heterogeneity of study effects: Pain tolerance (PTO) 
in response to noxious thermal (cold) stimuli, measured in seconds tolerated 
Pooled effect estimates of PTO in response to noxious thermal (cold) stimuli, measured by 
seconds tolerated, differed significantly by treatment group (p<0.001).  There was a 
significantly greater difference between exposed patients and controls in studies assessing 
patients with opioid use disorder (SMD = -2.78; 95% CI = -3.748 to -1.811; k = 12) compared 
with studies assessing patients with pain (SMD = -0.84; 95% CI = -1.810 to 0.123; k = 6), 
indicating elevated pain sensitivity in patients with opioid use disorder compared to patients 
with pain.  The meta-regression model was statistically significant (Q=5.26; df=1; p=0.022).  
Patients with opioid use disorder were associated with almost twice the difference between 
exposed patients and controls compared with patients treated for pain (coefficient = -1.829; 
95% CI = -3.392 to -0.266).  The coeffici nt was negative, indicating that patients with opioid 
use disorder were significantly associated with lower PTO (i.e. greater pain sensitivity) than 
patients with pain.  The meta-regression showed that the inclusion of this subgroup variable 
in the regression model explained 6% of the overall variance in study effects (R
2
=0.06). 
 
Pooled effect estimates of PTO in response to noxious thermal (cold) stimuli, measured in 
seconds tolerated, differed significantly by NMDA receptor antagonist treatment (p<0.001).  
There was a significantly greater difference between exposed patients and controls in 
studies where NMDA receptor antagonists were used (SMD = -2.96; 95% CI = -4.073 to -
1.854; k = 10) compared with opioids with no NMDA receptor antagonist properties (SMD = -
1.21; 95% CI = -2.223 to -0.202; k = 8), indicating elevated pain sensitivity in patients treated 
with NMDA receptor antagonists.  The meta-regression model was statistically significant 
(Q=4.69; df=1; p=0.030).  Treatment with opioids with NMDA receptor antagonist activity 
was associated with almost twice the difference between exposed patients and controls 
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compared with the use of non-NMDA receptor antagonists (coefficient = -0.701; 95% CI = -
3.239 to -0.162).  The coefficient was negative, indicating that patients in receipt of NMDA 
receptor antagonists were significantly associated with lower PTO (i.e. greater pain 
sensitivity) than patients treated with non-NMDA receptor antagonists.  The meta-
regression showed that the inclusion of this subgroup variable in the regression model 
explained less than 1% of the overall variance in study effects (R
2
<0.01). 
 
Meta-regression of the standardised difference in means on mean morphine-equivalent 
opioid dose was significant (Q=6.25; df=1; p=0.012); the regression line is shown in Figure 5. 
 
[Insert Figure 5 around here] 
 
The standardised differences in mean PTO between exposed patients and controls 
decreased significantly as a function of increasing mean morphine-equivalent opioid dose 
(coefficient = -0.0014; 95% CI = -0.0025 to 0.0003), indicating that increasing doses were 
associated with increased PTO (i.e. less pain sensitivity).  The meta-regression showed that 
the inclusion of this subgroup variable in the regression model explained 9% of the overall 
variance in study effects (R
2
=0.09). 
 
Subgroup analyses and examination of heterogeneity of study effects: Pain tolerance (PTO) 
in response to noxious thermal (heat) stimuli, measured in degrees Celsius tolerated 
All studies included only patients treated for pain and none used opioids with NMDA 
receptor antagonist properties.  Mean opioid dose was reported in two of the three studies 
but there were insufficient data to generate a meta-regression model. 
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Discussion 
Summary of evidence 
The primary objective of the current review was to undertake a systematic review and meta-
analysis of studies examining evidence for OIH in humans following chronic opioid exposure.  
Electronic and manual searches generated a total of 6167 articles, 26 of which (involving 
2706 participants) were retained for synthesis is the present review.  Pooled summary effect 
estimates were generated using the random effects (DerSimonian-Laird method) model, and 
individual studies were weighted in accordance with the principle of inverse variance. 
 
Findings suggested that there was evidence of OIH following chronic opioid exposure in 
response to noxious thermal stimuli assessed by pain tolerance.  There was, however, little 
evidence to suggest that OIH can be identified using assessments of pain detection 
threshold.  There was no significant group difference associated with noxious electrical 
stimuli; however, all but one of these studies also assessed pain threshold and tolerance in 
response to the cold pressor test, and participants taking opioids were found to have 
significantly lower threshold and tolerance values than those who were not.  There was no 
significant publication bias but substantial heterogeneity in study effects was identified. 
 
Subgroup analyses were computed where there were significant differences between 
exposed patients and controls and there were sufficient data to undertake subgroup 
analyses: pain threshold in response to noxious electrical stimuli; and pain tolerance in 
response to noxious thermal (cold) stimuli (measured in seconds tolerated).  OIH was 
significantly more evident in patients with opioid use disorder than in patients treated for 
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pain in both modalities.  However, this finding accounted for just 6% of variance in study effects in 
the thermal (cold) pain modality, most of the remaining variance being explained by other factors 
not amenable to meta-analysis.  OIH was significantly more evident in samples treated with 
NMDA receptor antagonists but this group difference accounted for less than 1% of variance 
in study effects in both modalities.  There was no effect of opioid treatment dose on OIH in 
response to noxious electrical stimuli but higher doses were significantly associated with 
decreased pain sensitivity in response to thermal (cold) stimuli.  This finding did not account 
for any variance in study effects. 
 
Findings in context 
The findings of the current meta-analysis suggest that OIH plays a role in the relative lack of 
long-term effectiveness of opioid analgesics that has been reported recently
49
.  Given that 
opioids leads to increased pain sensitivity despite the objective of achieving effective 
analgesia, an individual’s overall pain experience may be worse than before treatment, or at 
least not as good as it might be with non-opioid analgesia.  OIH is characterised by 
aggravated pain compared with pain experienced prior to opioid use, or with the de novo 
development of pain in the absence of pathology.  In consequence, it may also contribute to 
the high prevalence of chronic pain reported in patients in receipt of opioid replacement 
therapy for the treatment of opioid dependence
50
, whereby chronic opioid administration 
contributes to exacerbation of pain or the development of pain in these patients. 
 
Whilst evidence of OIH was fairly consistent across thermal experimental pain models 
assessed by pain tolerance, elevated pain sensitivity was not observed in patients in 
response to noxious electrical stimulation; however, in these same patients OIH was 
demonstrated in response to cold pressor testing.  This finding replicates previous findings 
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reported in the literature
51
.  It is not clear why the findings of these tests differed; however, 
there could be several potential reasons for this disparity.  First, short bursts of electrical 
stimulation are likely to elicit phasic pain whilst the relatively longer-term exposure in 
thermal pain models is likely to elicit tonic pain, relatively more similar to clinical pain
52
.  It is 
proposed that each model is associated with different pain qualities
53
 and different 
neurophysiological pathways and pharmacological modes of action
54
.  Indeed, in a factor 
analysis of responses to different pain modalities
55
, five factors were identified, including 
thermal and electrical noxious stimuli, and there was shown to be little correlation between 
these factors.  In conclusion, the authors recommended that a multi-modal experimental 
pain approach be used in assessing responses to noxious stimuli.  Secondly, pain has crucial 
adaptive functions in daily life which serve as a warning mechanism in the presence of 
harmful stimuli
56
.  The role of pain is of clear value in the presence of thermal or mechanical 
stimulation, which are relatively common in daily life, but its value in response to electrical 
stimulation is less obvious, since air is a poor conductor of electricity and, in consequence, 
humans have not developed electroreception.  Whilst the authors are not aware of any work 
in this specific area, it may be possible that, in evolutionary terms, central and peripheral 
nociceptive responses to thermal stimuli are ‘hardwired’ in human physiology but that 
responses to relatively uncommon stimuli, such as electricity, function differently.  Further 
comparison of nociceptive responses in different experimental pain modalities is required to 
ensure the validity of assessment methods. 
 
The psychometric properties of QST techniques using electrical experimental pain models 
are not as well-established as those of thermally-induced pain, and, since there are no 
objective, clinically-observable effects of central sensitisation, only face validity can be 
examined and construct validity, therefore, has not been established.  Whilst the face 
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validity and reliability of thermally-induced pain have been well-examined
57
, further 
assessment of other experimental pain modalities is required.  In the meantime, future 
research studies should consider using a battery of tests conducted in different experimental 
pain modalities to verify findings.  QST techniques are not currently used in clinical practice
58
 
but, following robust validation of these methods, they could prove valuable in helping to 
distinguish between opioid tolerance and OIH by facilitating testing specifically at non-
painful sites. 
 
Whilst it is generally assumed that the presence of OIH impacts on both pain detection 
threshold and pain tolerance, the findings of this review suggest assessment of pain 
tolerance is more effective in identifying hyperalgesic states.  These findings are difficult to 
interpret without further empirical examination; however, they may reflect the findings of 
Harris and Rollman
59
.  Using the Campbell and Fiske
60
 multitrait-multimethod matrix, they 
established a correlation matrix using pain modalities (i.e. multitrait) and measures of pain 
threshold and pain tolerance (i.e. multimethod) to evaluate convergent and discriminant 
validity.  They concluded that pain threshold and pain tolerance indicate different 
components of the pain experience, since correlations were higher for threshold (and for 
tolerance) across pain modalities than they were for threshold and tolerance within each 
modality.  It is, therefore, important that future studies assess both indices in the evaluation 
of responses to experimental pain. 
 
Hyperalgesic states were more evident in patients with opioid use disorder than in patients 
with pain.  Compared with many other clinical populations, patients with opioid use 
disorders are likely to experience greater life stress
61
 and to have higher prevalence of 
chronic illness, multimorbidity and attendance at emergency departments
62
.  It is, therefore, 
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important that health assessments of these individuals control for a range of factors, 
including affective characteristics and coping styles, which may impact on judgements of the 
pain experience.  Patients in receipt of ORT are likely to be in receipt of higher average 
equivalent opioid doses than patients with pain
15
 and this significant group difference may 
substantiate the dose-dependent relationship between opioids and hyperalgesia reported in 
a number of studies
1 2 3 4 
.  The present review, however, found that elevated opioid doses 
were significantly associated with lower pain sensitivity.  This finding requires further 
replication but may suggest that, in a proportion of patients at least, suspected hyperalgesia 
actually reflects inadequate analgesic treatment.  Indeed, in an evidence-based, structured 
review of the literature on OIH, Fishbain and colleagues
63
 reported having excluded articles 
due suspected OIH being identified as inadequate analgesic treatment. 
 
The hypothesised lower pain sensitivity associated with NMDA receptor antagonist 
treatments was not evidenced; however, there may have been a confounding effect of 
group since most patients in receipt of NMDA receptor antagonists were treated with 
methadone-maintenance therapy for the treatment of opioid use disorders.  Furthermore, 
this finding may be related to evidence suggesting that methadone has low NMDA receptor 
affinity
64
, whereby one might anticipate no effect of methadone, and heightened pain 
sensitivity may be an effect of continued illicit opioid use in these patients (i.e. higher dose 
consumption than is recorded for these individuals).  Further empirical examination of the 
role of NMDA receptor antagonism in OIH, and indeed in opioid tolerance, is required; this 
may involve the use of opioids with NMDA receptor antagonism properties or adjunctive 
NMDA antagonists to treat chronic pain, whilst ensuring rigorous control of substance 
misuse in study participants. 
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Limitations 
A substantial limitation was that, due to the nature of observational studies, pooled studies 
were not identical regarding comparator group characteristics or study designs.  Randomised 
controlled trials would be unethical in this field of study; however, the limitations associated 
with pooling observational studies should be borne in mind and findings should be 
interpreted with caution.  One further limitation was that only 25% of included articles were 
assessed by an independent reviewer. Whilst this is an approach sometimes used
47 48
, 
reviews could be strengthened further by independent review of all included articles, as 
recommended by most methods and reporting guidelines for systematic reviews. 
 
Conclusions 
Whilst there is some evidence to suggest that tolerance and dependence should be a 
concern
65
 when administering opioids, OIH should also be of concern to anaesthetists and 
other pain specialists.  The present review provides evidence for OIH in humans but this 
evidence is dependent upon the assessment metric and the nature of the noxious stimulus.  
Hyperalgesic states were more evident in patients with opioid use disorder and in treatment 
populations receiving opioids with NMDA receptor antagonist properties, but this primarily 
involved methadone-maintained, opioid-dependent patients.  Further studies must include 
evaluation of both pain threshold and pain tolerance across several pain modalities and 
must ensure more rigorous control of relevant characteristics within treatment groups – 
such as substance misuse, affective components or coping styles – and may consider using 
adjunctive NMDA receptor antagonists in attempting to identify effective treatment 
strategies whilst reducing the potential impact of opioid-induced hyperalgesia. 
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Figure legends 
Figure 1: Eligibility screening procedures and the total number of articles included in the 
review, shown on the PRISMA four-phase flow diagram 
 
Figure 2: Number of samples (k=65) included in the review, by research question.  Where 
meta-analyses or qualitative syntheses were undertaken, these numbers are shaded in dark 
red.  Beneath that are the numbers included in each treatment group.  Meta-analyses were 
undertaken where data were available from three or more studies.  [OUD=opioid use 
disorder.] 
 
Figure 3: Meta-analysis (random effects model) – pooled study findings of pain tolerance 
(PTO) in response to thermal (cold) experimental pain, measured in seconds tolerated, at a 
non-painful site in patients in receipt of opioid therapy. 
 
Figure 4: Meta-analysis (random effects model) – pooled study findings of pain tolerance 
(PTO) in response to thermal (heat) experimental pain, measured in degrees Celsius 
tolerated, at a non-painful site in patients in receipt of opioid therapy. 
 
Figure 5: Regression of standardised difference in means on mean oral morphine-equivalent 
opioid dose per day (mg) 
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Study name Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Compton (1994) -0.294 0.171 0.029 -0.629 0.040 -1.725 0.085
Compton (2000) -0.590 0.187 0.035 -0.956 -0.225 -3.165 0.002
Compton (2001) -0.795 0.299 0.089 -1.380 -0.210 -2.662 0.008
Doverty (2001) -7.541 2.014 4.055 -11.488 -3.595 -3.745 0.000
Doverty (2001a) -7.379 0.988 0.976 -9.315 -5.443 -7.470 0.000
Chu (2006) 0.775 0.599 0.358 -0.398 1.949 1.295 0.195
Athanasos (2006) -4.893 0.764 0.583 -6.390 -3.397 -6.408 0.000
Pud (2006) -0.605 0.180 0.032 -0.957 -0.252 -3.361 0.001
Eisenberg (2007) -0.549 0.192 0.037 -0.925 -0.173 -2.862 0.004
Hay (2009) -3.942 0.639 0.409 -5.195 -2.688 -6.164 0.000
Ram (2009) -0.051 0.202 0.041 -0.446 0.345 -0.252 0.801
Hay (2009i) -3.847 0.755 0.570 -5.326 -2.367 -5.095 0.000
Ho (2011) -1.548 0.218 0.048 -1.975 -1.121 -7.103 0.000
Compton (2012) -1.417 0.264 0.070 -1.933 -0.900 -5.371 0.000
Treister (2012) -0.594 0.204 0.042 -0.994 -0.193 -2.906 0.004
Suzan (2013) 0.318 0.367 0.135 -0.401 1.037 0.867 0.386
Wachholtz (2014) -6.458 0.531 0.282 -7.499 -5.418 -12.168 0.000
Edwards (2016) 0.000 0.254 0.065 -0.498 0.498 0.000 1.000
Zahari (2016) -2.949 0.167 0.028 -3.276 -2.622 -17.678 0.000
-1.833 0.319 0.102 -2.458 -1.208 -5.750 0.000
-8.00 -4.00 0.00 4.00
Lower PTO Higher PTO
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Study name Subgroup within studyOutcome Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Valuep-Value
Chen (2009)Overall PTO -5.695 0.453 0.205 -6.583 -4.806 -12.565 0.000
Hina (2015) Overall PTO -0.518 0.250 0.063 -1.009 -0.027 -2.069 0.039
Zhang (2015)Overall PTO -6.315 0.309 0.096 -6.921 -5.708 -20.405 0.000
-4.168 2.086 4.353 -8.258 -0.079 -1.998 0.046
-8.00 -4.00 0.00 4.00
Lower PTO Higher PTO
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Table 1: Characteristics of included studies (n=26) 
Author (year) N Study design Study effect 
   Pain threshold Pain tolerance 
   Exp. Control Exp. Control 
Athanasos (2006)
22
 – opioid use disorder treatment group 
   Cold (seconds) 28 Cross-sectional ---- ---- 15 34 
   Electrical (volts) 28 Cross-sectional ---- ---- 54 65 
Chen (2009)
23
 –pain treatment group 
   Cold (Celsius) 99 Cross-sectional 10.9 8.4 3.3 0.5 
   Heat (Celsius) 99 Cross-sectional 43.8 45.3 48.6 50.1 
Chu (2006)
24
 –pain treatment group 
   Cold (seconds) 6 Pre-post 12.1 10.1 28.0 19.8 
Compton (1994)
25
 – opioid use disorder treatment group 
   Cold (seconds) 220 Cross-sectional ---- ---- 62 86.1 
Compton (2000)
26
 – opioid use disorder treatment group 
   Cold (seconds) 120 Cross-sectional   43.7 93.9 
Compton (2001)
27
 – opioid use disorder treatment group 
   Cold (seconds) 54 Cross-sectional   60.4 138 
Compton (2012)
28
 – opioid use disorder treatment group 
   Cold  103 Cross-sectional 9.38 11.79 18.26 41.54 
   Electrical (volts) 103 Cross-sectional 41.54 38.00 56.07 63.55 
Doverty (2001)
29
 – opioid use disorder treatment group 
   Cold (seconds) 8 Cross-sectional 7.3 7.4 25 57 
   Electrical (volts) 8 Cross-sectional 37 28 63 52 
Doverty (2001a)
30
 – opioid use disorder treatment group 
   Cold (seconds) 32 Cross-sectional 4 5 21 63 
   Electrical (volts) 32 Cross-sectional 34 28 54 63 
Edwards (2011)
31
 –pain treatment group 
   Cold (seconds) 276 Cross-sectional 15 18.32 ---- 45 
   Heat (seconds) 276 Cross-sectional 42 41 ---- 45 
Edwards (2016)
32
 –pain treatment group 
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   Cold (seconds) 31 Pre-post ---- ---- 40 40 
Eisenberg (2007)
33
 – opioid use disorder treatment group 
   Cold (seconds) 113 Cross-sectional 10.5 7.1 30.5 55.2 
Hay (2009)
15
 –pain treatment group 
   Electrical (volts) 25 Cross-sectional 35.6 34.8 48.1 52.6 
   Cold (seconds) 25 Cross-sectional 10.75 12.2 18.9 30.7 
Hay (2009)
15
 – opioid use disorder treatment group 
   Electrical (volts) 15 Cross-sectional 38.8 34.8 52.4 52.6 
   Cold (seconds) 15 Cross-sectional 8.9 12.2 18.9 30.7 
Hina (2015)
34
 –pain treatment group 
   Heat (Celsius) 68 Cross-sectional 43 43.5 47.1 48.4 
Ho (2011)
35
 – opioid use disorder treatment group 
   Cold (seconds) 111 Cross-sectional 11 9 24 34 
Krishnan (2012)
36
 – opioid use disorder treatment group 
   Electrical (volts) 32 Cross-sectional 63.5 37 65.5 59 
Peles (2010)
37
 – opioid use disorder treatment group 
   Cold (Celsius) 48 Cross-sectional 19.5 17.5 ---- ---- 
   Heat (Celsius) 48 Cross-sectional 44 43 ---- ---- 
Pud (2006)
38
 – opioid use disorder treatment group 
   Cold (seconds) 130 Cross-sectional 10.6 6.6 29.1 56.4 
Ram (2009)
39
 –pain treatment group 
   Cold (seconds) 110 Cross-sectional 9.9 10.1 22.8 24.1 
Reznikov (2005)
40
 –pain treatment group 
   Heat (Celsius) 224 Cross-sectional 45.4 45.7 ---- ---- 
Suzan (2013)
41
 –pain treatment group 
   Cold (seconds) 40 Cross-sectional ---- ---- 43.9 30.0 
Treister (2012)
42
 – opioid use disorder treatment group 
   Cold (seconds) 100 Cross-sectional 10.8 6.8 30.0 56.4 
Wachholtz (2014)
43
 –pain treatment group 
   Cold (seconds) 90 Cross-sectional 24.22 54.4 53.3 137.1 
Wang (2012)
44
 –pain treatment group 
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   Cold (Celsius) 63 Cross-sectional 11 9 ---- ---- 
   Heat (Celsius) 63 Cross-sectional 42 47 ---- ---- 
Zahari (2016)
45
 – opioid use disorder treatment group 
   Cold (seconds) 300 Cross-sectional ---- ---- 34.17 61.36 
Zhang (2015)
46
 –pain treatment group 
   Heat (Celsius) 250 Cross-sectional 43.7 44.7 48.8 49.9 
   Cold (Celsius) 250 Cross-sectional 11.2 9.4 3.88 0.56 
Note: Exp. = exposed 
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